Amvuttra in Nepal

Amvuttra - overview

Amvuttra (vutrisiran) is manufactured by Alnylam and indicated for hATTR-PN; ATTR-CM (2025). It is a siRNA approved by the US FDA in 2022 and may be accessible to patients in Nepal through a Named Patient Program or personal-import pathway.

Access in Nepal

Nepal's DDA has a personal-use pathway; volumes are small but process exists.

How Reserve Meds coordinates access in Nepal

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Nepal-specific eligibility.
3. Treating physician in Nepal issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Amvuttra from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Nepal.

Typical timeline for Nepal

End-to-end, most requests are completed in 2-6 weeks. Nepal's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Nepal ask

• Is the pathway legal in Nepal? Yes - it operates under Nepal's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Nepal able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Amvuttra in Nepal

Request Amvuttra